Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease (RORAAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01389388
Recruitment Status : Completed
First Posted : July 8, 2011
Last Update Posted : May 7, 2015
Information provided by (Responsible Party):
Anne Grete Semb, Diakonhjemmet Hospital

Brief Summary:

Patients with rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) are at greater risk of developing cardiovascular disease. The reason(s) for this have not been well investigated, but there is a general understanding that systemic inflammation plays a part in the increased cardiovascular morbidity and mortality. In spite of the increased risk in these patients, they have not been included as a high risk patient group in cardiovascular prevention guidelines.

The investigators have carried out a cardiovascular study of RA and AS patients, as well as patients with arthritis for the first time. The investigators have demonstrated cholesterol plaques in the carotid artery in some of these patients. Plaques in the carotid artery represent a risk for development of cerebral stroke and are significantly associated with myocardial infarction. These plaques, which are asymptomatic and do not cause haemodynamically significant narrowing, diameter reduction (i.e. operation is not indicated), are vascular atheromatous disease. Therefore, according to prevailing cardiovascular guidelines (SCORE 2007), these patients shall have secondary prevention with a lipid lowering agent with the LDL-cholesterol goal of 1.8 mmol/L and HDL-cholesterol > 1.0 mmol/L for men and > 1.1 mmol/L for women.

Statins are cholesterol-lowering drugs, and have been shown to reduce the risk of cardiovascular disease significantly. In addition, reduction in the size of coronary plaques has been induced by statins, when the LDL has been reduced to 1.6-1.8 mmol/l. Plaques in the carotid or coronary arteries have not previously been treated and characterized in patients with RA, AS and other inflammatory forms of arthritis.

The aim of this study is to treat patients with cholesterol plaques in the carotid artery with cholesterol-lowering medication, in the form of Rosuvastatin for 18 months, and characterize the effects on the plaques in the carotid and coronary arteries. In addition, the investigators want to clarify the connection between plaques in the carotid and coronary arteries in patients with RA, AS and other inflammatory forms of arthritis.

Condition or disease Intervention/treatment Phase
Carotid Artery Plaque Ankylosing Spondylitis Rheumatoid Arthritis Drug: Rosuvastatin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Cholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases
Study Start Date : January 2013
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: Rosuvastatin intervention
Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Drug: Rosuvastatin
All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Other Name: Brand name for Rosuvastatin is Crestor

Primary Outcome Measures :
  1. Carotid artery cholesterol plaque regression and stabilization [ Time Frame: 18 months ]
    Reduction of plaque area and change of the plaque morphology to less vulnerable for rupture after 18 months with 40 mg Rosuvastatin daily.

Secondary Outcome Measures :
  1. Disease activity and health measures, lipoprotein components and inflammatory biomarkers [ Time Frame: 18 months ]
    Disease activity and Health status i. Disease activity will be measured by: 28-swollen-joint count, AIMS2, BASDAI ii. Health status will be measured by MHAQ, BASFI, Pain VAS, Fatigue VAS, life quality (HRQoL)

  2. Carotid artery cholesterol plaque regression and stabilization [ Time Frame: 18 months ]
    Lipoprotein components: Lipids, apolipoproteins, magnitude and functional measurements of these, for example of HDL

  3. Carotid artery cholesterol plaque regression and stabilization [ Time Frame: 18 months ]
    Biomarkers/inflammation parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women and men with RA, AS and other inflammatory forms of arthritis, aged 35-80 years.
  2. Cholesterol plaques demonstrated in carotid artery by ultrasound.
  3. Informed consent.

Exclusion Criteria:

  1. Concomitant statin treatment
  2. Arterial fibrillation or others with chronic irregular heart rhythm (because of CT).
  3. Contraindication to statin treatment.

    • Hypersensitivity to statins
    • Liver disease with ASAT/ALAT ≥ twice the upper normal limit
    • Previous statin-induced myopathy or severe hypersensitivity reactions to other statins
    • Raised creatinine (because of contrast medium)
    • Pregnancy or breast feeding
    • Fertile women who do not use contraceptives
    • Cyclosporine treatment
    • Treatment with medicinal products that have a known interaction with Rosuvastatin
    • Uncontrolled hypothyroidism defined as TSH > 1.5 times ULN at the first visit (because of the connection between myopathy and hypothyroidism with statin treatment)
    • Creatinine clearance < 30 ml/min and <60 ml/min with a Rosuvastatin dose of 40 mg per day
  4. Secondary hyperlipidemia

    • Primary hyperthyroidism
    • Nephrotic syndrome, creatinine > 2 mg/dl
    • Uncontrolled diabetes mellitus (HbA1C > 10 %)
    • Plasma Triglycerides > 6.8 mmol/l
  5. Other diseases or treatment that reduces the safety, or treatment with Rosuvastatin which would interfere with the end points of the study

    • Heart failure: NYHA class III B/IV
    • Haemodynamically significant valve defects
    • Established statin treatment
    • Gastrointestinal disease/treatment that can give malabsorption of Rosuvastatin
    • Cancer
    • Severe psychiatric disease
    • Life-threatening ventricular arrhythmias
    • Other medication that increases the risk of rhabdomyolysis
    • Known abuse of alcohol
    • Participation in other studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01389388

Layout table for location information
Anne Grete Semb, Department of Rheumatology, Diakonhjemmet hospital
Oslo, Norway, NO-0319
Sponsors and Collaborators
Diakonhjemmet Hospital
Layout table for investigator information
Principal Investigator: Anne G Semb, MD, PhD Diakonhjemmet Hospital
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Anne Grete Semb, Leader of the Preventive Cardio-Rheuma clinic, Diakonhjemmet Hospital Identifier: NCT01389388    
Other Study ID Numbers: 2009/2219
2008-005551-20 ( EudraCT Number )
First Posted: July 8, 2011    Key Record Dates
Last Update Posted: May 7, 2015
Last Verified: May 2015
Keywords provided by Anne Grete Semb, Diakonhjemmet Hospital:
Carotid plaques
inflammatory joint disease
lipoprotein components
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Spondylitis, Ankylosing
Joint Diseases
Carotid Stenosis
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Bone Diseases, Infectious
Bone Diseases
Spinal Diseases
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents